Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status Prescription; Discontinued
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 54245-1359; 65344-0029; 54893-0036; 63850-8070; 53104-7700; 73377-128; 0310-0482; 61200-002; 46708-880; 68554-0060
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone pain15.02.01.0010.000533%
Breast cancer21.05.01.003; 16.10.01.0010.001066%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchopulmonary aspergillosis22.07.08.001; 11.03.01.0020.000139%Not Available
Bundle branch block02.03.01.009--Not Available
Cardiac failure02.05.01.001--
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cataract06.06.01.0010.000799%
Cellulitis23.09.01.001; 11.02.01.0010.000799%Not Available
Cerebral atrophy17.11.01.0010.000799%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.001865%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.001066%Not Available
Cholestasis09.01.01.0010.000799%Not Available
Colitis ischaemic24.04.08.012; 07.08.01.0040.000533%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.000208%Not Available
Coma17.02.09.0010.001865%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Corneal erosion06.06.03.003--Not Available
Cough22.02.03.0010.002131%
Creatinine renal clearance decreased13.13.01.0130.000533%Not Available
Cutaneous vasculitis24.05.02.004; 23.06.02.001; 10.02.02.003--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Cystitis haemorrhagic20.03.02.0030.000533%Not Available
Deafness04.02.01.0010.000799%Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Dementia19.20.02.001; 17.03.01.0010.000533%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages